HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $14.87.

Several research firms recently commented on HCM. Weiss Ratings upgraded shares of HUTCHMED from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, October 20th. Daiwa Securities Group raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Thursday, September 3rd. Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. The Goldman Sachs Group decreased their target price on HUTCHMED from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, July 23rd. Finally, HSBC upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Tuesday, September 8th.

HUTCHMED Stock Up 6.8%

HCM stock opened at $15.16 on Friday. The firm has a 50 day moving average of $13.80 and a two-hundred day moving average of $13.21. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.50. HUTCHMED has a 12 month low of $9.77 and a 12 month high of $16.33.

Institutional Trading of HUTCHMED

Several large investors have recently modified their holdings of HCM. XY Capital Ltd increased its holdings in HUTCHMED by 115.2% in the 2nd quarter. XY Capital Ltd now owns 104,130 shares of the company’s stock valued at $1,120,000 after acquiring an additional 55,736 shares during the last quarter. Crossmark Global Holdings Inc. boosted its position in shares of HUTCHMED by 25.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 106,185 shares of the company’s stock worth $1,553,000 after buying an additional 21,270 shares in the last quarter. Amundi lifted its stake in shares of HUTCHMED by 4.0% in the 1st quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after purchasing an additional 8,916 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of HUTCHMED during the first quarter worth $365,000. 8.82% of the stock is owned by institutional investors.

About HUTCHMED

HUTCHMED (NASDAQ:HCM) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company combines research and development capabilities in China with international development and commercial operations, serving patients and healthcare providers in China, the United States, Europe and other global markets.

HUTCHMED’s oncology portfolio includes fruquintinib, a targeted therapy for certain patients with metastatic colorectal cancer.